Boas Práticas de Farmácia Hospitalar - Portal da Saúde

168
Referências Bibliográficas
1 World Health Organization. Adherence to long therapies. Evidenceforaction. http://www.who.int/
chronic_conditions/adherence_report.pdf (Junho 2003)
2 Butler C. Christopher, Stephen Rollnick. Adesão ao tratamento médico. Elsevier Science 2003, pág 11
(Tradução)
3 Butler C. Christopher, Stephen Rollnick. Adesão ao tratamento médico. Elsevier Science 2003, pág 17
(Tradução)
4 Matsuyama J.R., Mason B., Jue S. (1993). Pharmacists interventions using an electronic medication
event monitoring devices adherence data versus pill counts. Annals Pharmac., 27, 851-4
5 T. Sasis P. Adherence to highly active antiretroviral therapy. AIDS 2001; 15:109-15
6 Butler C. Christopher, Stephen Rollnick. Adesão ao tratamento médico. Elsevier Science 2003, pág 15
(Tradução)
7 Palella F., Delaney K., Moorman A., Loveless M., Fuhrer J., et al. (1998) Declining morbidity and mortality
among patientes with advanced human imunodeficiency virus infection. NEJM, 338, 853-60
8 Panel on Clinical Practices for the treatment of HIV infection. (2005). Guidelines for the use of antiretroviral
agents in HIV infected adults and adolescents. Department of Health and Human Services.
www.AIDSinfo.nih.gov (Outubro 2006)
9 Haubrich R.H, Litle S.J, Currier J.S., Forthal D.N., Kemper C.A., Gildon N.B., Johnson D., Dubé M.P.,
Hwang J.Y., McCutchan J.A., and the California Collaborative (1999) .The value of patient-reported
adherence to antiretroviral therapy in predicting virologic an immunologic response. AIDS, 13, 1099-107
10 Paterson D., Swindells S., Mohr J., Brester M. Vergis E.N., Squier C., Wagener M., Singh N. (2000).
Adherence to protease inhibitor therapy and outcome with HIV infection. Ann. Inter. Med., 133, 21-30
11 Wainberg M.A, Friedand G. (1998) Public Health implications of antiretroviral therapy and drug
resistence. JAMA, 297(24), 1977-83
12 Freedberg K.A., Losina E., Weinstein M.C., Paltiel D., Cohen C.J. et al.(2001) The Cost-Effectiveness
of Combination Antiretroviral Therapy for HIV Disease. NEJM, 344, 824-31
13 Bond W.S., Hussar D.A. (1991). Detection methods and strategies for improving medication compliance.
Am J Hosp Pharm, 48, 1978-88
14 Duong M., Piroth L., Peytavin G., Forte F., Kohli E., Grappin M., Buisson M., Chavanet P., Portier H.
(2001). Value of Patient Self-Report and Plasma Human Immunodeficiency virus protease inhibitor level
as markers of adherence to antiretroviral therapy: relationship to virologic response. Clin. Inf. Dis., 33,
386-92
15 Hugen P.W., Langebeek N., Burger D., Zomer B., Van Leusen R., Schuurman R., Koopmans P., Hekster
Y. (2002). Assessement of adherence to HIV protease inhibitors: comparison and combination of various
methods, including MEMS, patient and nurse self report and drug monitoring. JAIDS, 30(3), 324-34
16 Alcoba M., Cuevas M.J., Perez-Simon M.R., Mostaza J.L., Ortega L., Ortiz de Urbina J., Carro J.,
Raya C., Abad M., Martin V. (2003). Assessment of adherence to triple antiretroviral treatment including
indinavir: role of the determination of plasma levels of indinavir. JAIDS, 33, 253-8
17 Dorz S., Lazzarini L., Cattelan A., Meneghetti F., Novara C., Concia E., Sica C., Sanavio E. (2003).
Evaluation of adherence to antiretroviral therapy in Italian HIV patients. AIDS Patient Care and STDs, 17,
33-41